Brandes Investment Partners LP Purchases 45,860 Shares of CVS Health Corporation $CVS

Brandes Investment Partners LP lifted its position in CVS Health Corporation (NYSE:CVS) by 2.5% in the 4th quarter, HoldingsChannel.com reports. The fund owned 1,845,342 shares of the pharmacy operator’s stock after acquiring an additional 45,860 shares during the quarter. Brandes Investment Partners LP’s holdings in CVS Health were worth $146,447,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in shares of CVS Health by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 120,709,530 shares of the pharmacy operator’s stock worth $9,579,508,000 after acquiring an additional 1,824,424 shares in the last quarter. Capital World Investors grew its stake in shares of CVS Health by 2.1% in the 3rd quarter. Capital World Investors now owns 68,382,158 shares of the pharmacy operator’s stock worth $5,155,380,000 after acquiring an additional 1,419,575 shares in the last quarter. State Street Corp grew its position in CVS Health by 0.3% during the third quarter. State Street Corp now owns 58,938,286 shares of the pharmacy operator’s stock valued at $4,443,357,000 after buying an additional 149,701 shares during the period. Capital International Investors grew its position in CVS Health by 3.4% during the fourth quarter. Capital International Investors now owns 27,592,356 shares of the pharmacy operator’s stock valued at $2,189,793,000 after buying an additional 900,153 shares during the period. Finally, Invesco Ltd. grew its position in CVS Health by 3.2% during the third quarter. Invesco Ltd. now owns 24,293,058 shares of the pharmacy operator’s stock valued at $1,831,454,000 after buying an additional 760,579 shares during the period. Institutional investors own 80.66% of the company’s stock.

Insider Transactions at CVS Health

In other CVS Health news, Director Larry Robbins sold 1,983,538 shares of the stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the completion of the transaction, the director owned 6,213,261 shares in the company, valued at $586,842,501.45. This trade represents a 24.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the transaction, the executive vice president owned 10,133 shares of the company’s stock, valued at $907,714.14. This represents a 87.28% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 3,441,551 shares of company stock valued at $323,703,977 in the last quarter. Company insiders own 0.85% of the company’s stock.

Analyst Ratings Changes

CVS has been the subject of several research reports. Truist Financial increased their price target on shares of CVS Health from $102.00 to $108.00 and gave the company a “buy” rating in a research report on Monday, June 1st. Robert W. Baird increased their price target on shares of CVS Health from $92.00 to $94.00 and gave the company an “outperform” rating in a research report on Wednesday, April 15th. Weiss Ratings restated a “hold (c)” rating on shares of CVS Health in a research report on Friday, May 8th. TD Cowen increased their price target on shares of CVS Health from $105.00 to $110.00 and gave the company a “buy” rating in a research report on Monday, May 11th. Finally, Deutsche Bank Aktiengesellschaft increased their price target on shares of CVS Health from $88.00 to $92.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Twenty-two analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $100.68.

CVS Health Price Performance

Shares of NYSE:CVS opened at $96.97 on Wednesday. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78. The firm has a market capitalization of $123.73 billion, a PE ratio of 42.72, a P/E/G ratio of 0.95 and a beta of 0.62. CVS Health Corporation has a twelve month low of $58.50 and a twelve month high of $98.43. The company has a 50-day moving average price of $85.19 and a two-hundred day moving average price of $80.32.

CVS Health (NYSE:CVS) last issued its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, topping analysts’ consensus estimates of $2.21 by $0.36. The firm had revenue of $100.43 billion during the quarter, compared to analyst estimates of $94.99 billion. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The company’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter last year, the business earned $2.25 earnings per share. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Equities analysts forecast that CVS Health Corporation will post 7.44 EPS for the current year.

CVS Health Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, May 4th. Shareholders of record on Thursday, April 23rd were given a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date was Thursday, April 23rd. CVS Health’s dividend payout ratio (DPR) is currently 117.18%.

Trending Headlines about CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: UBS raised its price target on CVS to $115 from $100 and reiterated a buy rating, signaling confidence that the shares can still move higher. UBS adjusts price target on CVS Health to $115 from $100, maintains buy rating
• Positive Sentiment: The company continues to highlight growth initiatives, including expanded GLP-1 access, new AI and patient-care programs, and a new CFO appointment for its health care delivery business, all of which suggest ongoing investment in operational execution. CVS Health valuation check as GLP-1 access expands and PBM scrutiny intensifies
• Positive Sentiment: CVS also received recognition for technology that improves medication safety and patient care, reinforcing its push to position itself as a broader health services company rather than only a pharmacy chain. CVS Health recognized for technology that improves medication safety and patient care

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.